Overview

A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study is conducted to select the THR-149 dose level (Part A of the study) and to assess the efficacy and safety of the selected dose level compared to aflibercept (Part B of the study).
Phase:
Phase 2
Details
Lead Sponsor:
Oxurion
Treatments:
Aflibercept